Disease recurrence was higher in the group with low ER pathway activity, suggesting reduced effectiveness of endocrine therapy in this group.

Multi-pathway analysis may provide direction for alternative therapy

Further analysis of the ER inactive group revealed aberrant activity of other pathways (see PI3K pathway in patient example) relative to reference tissue (grey ranges), suggesting that another therapeutic approach maybe more effective.

In the MCF7 cell line with higher initial PI3K activity, drug-induced inhibition of PI3K pathway activity corresponds to inhibition of cell growth. In the MDA-MB-231 cell line with lower initial PI3K activity, drugs are less effective.

OncoSignal pathway analysis in PDX models

Activity of different signaling pathways in PDX models (Charles River Laboratories). Depending on the postulated mode of action of the drug, OncoSignal may help select the PDX model with the optimal pathway activity profile. Based on the activity profiles depicted below, the PDX 713 and 508 models were selected to test PI3K inhibiting drugs.

The two selected PDX models show relatively high PI3K pathway activity in the vehicle group and reduction of pathway activity in the treated groups (data not shown), which coincides with a reduction in tumor growth by various PI3K inhibitors. In the PDX 713 model with the highest PI3K activity in the vehicle group, an almost complete tumor growth inhibition was observed. The PDX 508 model with lower PI3K activity showed less inhibition, stressing the value of OncoSignal testing in the course of your experiment.

For more cancer-type or pathway specific publications, please email us at oncosignal@philips.com.

Now available: OncoSignal service testing

OncoSignal pathway analysis is now available through our dedicated service lab. For more information or a dedicated quotation, please contact the OncoSignal team at oncosignal@philips.com

OncoSignal Service Testing features:

A pathway activity report delivered per sample with quantitative scores of relevant pathways.

Sample types: FFPE or FF human tissues, cell lines, PDX.

Optimized for small sample sizes.

qPCR kits enabling in-house pathway analysis with short turnaround time are in development.

Pathway analysis based on RNAseq data in development.

News & upcoming events

Upcoming events

OncoSignal at AMP 2018

AMP 2018 Annual Meeting in San Antonio

1-3 November

Booth #519

OncoSignal at ENA 2018

EORTC-NCI-AACR 2018 in Dublin

13-16 November
Booth #A3

OncoSignal at SABCS 2018

SABCS 2018 in San Antonio

5-7 December
Booth #520

OncoSignal at ESMO 2018

ESMO 2018 in Munich

19-22 October
Booth #141

News

OncoSignal at AACR 2018: OncoSignal tests for pre-clinical research

During the AACR Annual Meeting 2018, we introduced the OncoSignal tests for pre-clinical research. Please view the dedicated flyer for a summary of benefits and supporting data.

Part of these data were generated in collaboration with Charles River Laboratories (CRL). During the AACR Annual Meeting, Anja van de Stolpe (MD and co-inventor of OncoSignal pathway analysis) participated in a Charles River panel to elaborate on the meaning and purpose of signaling pathway analysis in the oncology field (see video). In addition, OncoSignal findings are now accessible through the CRL compendium

By clicking on the link, you will be leaving the official Royal Philips Healthcare ("Philips") website. Any links to third-party websites that may appear on this site are provided only for your convenience and in no way represent any affiliation or endorsement of the information provided on those linked websites. Philips makes no representations or warranties of any kind with regard to any third-party websites or the information contained therein.